Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Consensus Recommendation of “Hold” from Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been assigned an average recommendation of “Hold” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $14.00.

A number of research firms have issued reports on ATRA. Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their price target for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. The Goldman Sachs Group reduced their target price on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a report on Wednesday, July 17th. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday, August 21st. Canaccord Genuity Group reiterated a “buy” rating and set a $13.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, August 13th. Finally, StockNews.com assumed coverage on Atara Biotherapeutics in a research note on Wednesday, June 26th. They issued a “hold” rating on the stock.

Institutional Trading of Atara Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Atara Biotherapeutics in the second quarter worth about $53,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Atara Biotherapeutics during the 2nd quarter valued at about $79,000. Delap Wealth Advisory LLC purchased a new position in shares of Atara Biotherapeutics in the 1st quarter valued at about $29,000. BNP Paribas Financial Markets raised its holdings in Atara Biotherapeutics by 29.3% in the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 86,842 shares during the period. Finally, Acadian Asset Management LLC boosted its position in Atara Biotherapeutics by 49.5% during the first quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after purchasing an additional 873,133 shares in the last quarter. Institutional investors and hedge funds own 70.90% of the company’s stock.

Atara Biotherapeutics Price Performance

Shares of ATRA stock opened at $7.69 on Friday. The business has a fifty day moving average of $8.01 and a 200 day moving average of $11.92. Atara Biotherapeutics has a 1 year low of $4.96 and a 1 year high of $45.75. The firm has a market capitalization of $37.04 million, a price-to-earnings ratio of -0.14 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($1.54). The firm had revenue of $28.64 million during the quarter, compared to analyst estimates of $48.30 million. As a group, equities research analysts expect that Atara Biotherapeutics will post -12.09 earnings per share for the current year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.